peptideone
← All peptides

Bremelanotide

Status unknown

Also known as: 189691-06-3, Bremelanotida, 6Y24O4F92S, PT-141 FREE BASE, PT 141, (3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid, DTXSID40893711, L-Lysine, N-acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, (2->7)-lactam

Bremelanotide (189691-06-3, Bremelanotida, 6Y24O4F92S) is classified under melanocortin agonists.

What the research says

Aggregated from the cited literature below. We summarize sources — we don't author claims.

Bremelanotide is a synthetic cyclic peptide analogue described as a melanocortin receptor agonist. Research reported that it has been studied for hypoactive sexual desire disorder (HSDD) and that it received FDA approval in the USA for acquired, generalized HSDD in premenopausal women. Source articles also summarize development milestones and clinical trial evidence (including phase 2 and phase 3 studies). (PMIDs: 31369224, 31893927, 36809187, 31599840)

Mechanism (as reported)

A study described bremelanotide as having high affinity for the melanocortin type 4 (MC4) receptor and as a modulator of brain pathways involved in sexual response; it is hypothesized to trigger excitatory brain pathways via central melanocortin signaling. (PMIDs: 31369224, 36242769)

Key findings (each cites a source)

  • Bremelanotide is described as an MC4-receptor agonist and a synthetic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) with high affinity for the melanocortin type 4 receptor; it is discussed as potentially modulating brain pathways involved in sexual response. (PMIDs: 31369224, 36242769) [PMID 31369224, 36242769]
  • A development/milestones summary reported that bremelanotide was approved in the USA for the treatment of premenopausal women with acquired, generalized HSDD. (PMIDs: 31369224) [PMID 31369224]
  • A review reported that phase 2 and phase 3 trials of bremelanotide were included, and it described statistically significant improvements in sexual desire and reductions in distress related to lack of desire. (PMIDs: 31893927) [PMID 31893927]
  • Two randomized phase 3 trials (RECONNECT; studies 301 and 302) reported that bremelanotide increased sexual desire and reduced distress related to low sexual desire compared with placebo, with statistically significant changes in coprimary endpoints. (PMIDs: 31599840) [PMID 31599840]
  • Across the phase 3 program safety review, the most common adverse events (in integrated phase 3 double-blind data) were nausea, flushing, headache, and injection site reactions; it also reported no deaths and described a rare occurrence of focal hyperpigmentation under certain dosing patterns. (PMIDs: 36809187) [PMID 36809187]
  • A review reported that the most common adverse effects included nausea (39.9%), facial flushing (20.4%), and headache (11%). (PMIDs: 31893927) [PMID 31893927]
  • A safety-profile review described most drug-drug interactions as not clinically significant, except for interactions that lowered plasma concentrations of indomethacin and naltrexone. (PMIDs: 36809187) [PMID 36809187]
  • Measurement/validity research reported questionable validity evidence for several continuous efficacy outcomes and found no validity evidence for previously published categorical treatment response outcomes from the RECONNECT phase 3 trials; it characterized overall benefits as statistically modest and limited to outcomes with scant evidence of validity. (PMIDs: 36809187) [PMID 36809187]
  • A review discussed that overall clinical benefit appears modest and highlighted challenges in interpreting efficacy due to placebo effect and outcome measures susceptible to expectation biases. (PMIDs: 36242769) [PMID 36242769]
  • A breastfeeding-focused statement reported that no clinical use information was available during breastfeeding and suggested that infant absorption is unlikely because the peptide is likely destroyed in the infant gastrointestinal tract, while advising caution until more data are available. (PMIDs: 31369224) [PMID 31369224]

Independent test grades

No independent third-party test data is available for Bremelanotide yet. Our test grades are aggregated from Finnrick, which independently tests a subset of research peptides — many approved drugs and newer or niche compounds aren't covered.

Research literature (8)

Consolidated from PubMed — each links to the original record.

FAQ

What is Bremelanotide?
Bremelanotide (189691-06-3, Bremelanotida, 6Y24O4F92S) is classified under melanocortin agonists. Research goals associated with it include sexual & reproductive.
Is Bremelanotide FDA-approved?
The regulatory status of Bremelanotide is not established in our sources.
What does the research on Bremelanotide say?
peptideone aggregates 8 references from PubMed for Bremelanotide. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.
Aggregated from public sources, with attribution. Not medical advice; compounds discussed are not approved for human consumption. Last updated 2026-06-15.